Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.

A study in a dietary model of nonalcoholic steatohepatitis in rats.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis.

To the team's surprise, they realized that the mice were in fact in the advanced stages of nonalcoholic steatohepatitis.

The other 20% will develop a disease called nonalcoholic steatohepatitis, or NASH.

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Liver disease called nonalcoholic steatohepatitis.

Nonalcoholic steatohepatitis (if progression to cirrhosis has occurred)

Some evidence suggests that taking melatonin improves markers of liver function in the blood of people with nonalcoholic steatohepatitis.

Nonalcoholic steatohepatitis (NASH) is a common and potentially severe form of liver disease.

Nonalcoholic steatohepatitis (NASH)

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.

Temporal trends in liver transplantation (LT) for nonalcoholic steatohepatitis (NASH)

This early-stage health condition can sometimes progress to more serious, even fatal diseases, including nonalcoholic steatohepatitis, or NASH, as well as cirrhosis and liver cancer.

The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin.

In industrialized countries, the main causes of liver injury leading to fibrosis include chronic hepatitis virus infection, excess alcohol consumption and, increasingly, nonalcoholic steatohepatitis (NASH).

One severe, progressive form of non-alcoholic fatty liver disease is nonalcoholic steatohepatitis, which can lead to cirrhosis and even liver cancer, they note in the medical journal Gastroenterology.

Early research suggests that taking vitamin C together with vitamin E might improve some aspects of liver function in people with a certain liver disease called nonalcoholic steatohepatitis.

Podymova S. D., Davletshina I. V. [Efficacy of using alpha-lipoic acid (berlition) in patients with nonalcoholic steatohepatitis].

When not associated with excessive alcohol intake, it is referred to as nonalcoholic steatohepatitis (NASH), and is the progressive form of the relatively benign non-alcoholic fatty liver disease.

It provides information on autoimmune hepatitis, primary biliary cirrhosis, fatty liver, nonalcoholic steatohepatitis, alcoholic liver disease, hemochromatosis, benign and gives malignant liver tumors and other diseases of iron overload.

Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease.

Tanaka, N., Sano, K., Horiuchi, A., Tanaka, E., Kiyosawa, K., and Aoyama, T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis.

Harrison, S. A., Torgerson, S., Hayashi, P., Ward, J., and Schenker, S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.